Anti‑angiogenic therapy for normalization of tumor vasculature: A potential effect of Buyang Huanwu decoction on nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential

抗血管生成治疗使肿瘤血管正常化:补阳还五汤对高转移潜能人肝细胞癌异种移植瘤裸鼠的潜在影响

阅读:5
作者:Liang Min, Wei Ling, Rong Hua, Hong Qi, Shenxu Chen, Haiqiao Wang, Lumen Tang, Wenji Shangguan

Abstract

The present study aimed to investigate the effect of Buyang Huanwu decoction (BYHWD) on tumor growth, metastasis and angiogenesis in nude mice bearing human hepatocellular carcinoma (HCC) HCCLM3 xenografts. A total of 96 nude mice bearing HCCLM3 xenografts were randomly divided into four groups: BYHWD group (LB), Yi‑qi decoction group (LY), Huo‑xue decoction group (LH) and model group (LM). Each of these groups was divided into three subgroups (n=8), which were observed on days 21, 25, 38 following treatment, respectively. The tumor weights, volumes and pulmonary metastases were recorded. The expression of CD105 and the microvessel density (MVD) were assessed, and the expression levels of vascular endothelial growth factor (VEGF), hypoxia‑inducible factor 1α (HIF‑1α), and regulator of G protein signaling 5 (RGS‑5) were analyzed using immunohistochemical staining. Compared with the LM group, no significant decrease in tumor weight or volume were observed in the herbal medicine treatment groups, the number of the metastases in the lungs decreased, whereas the expression levels of RGS‑5 and HIF‑1α decreased in the LB group on day 35. However, the expression levels of VEGF increased in the LB group on days 28 and 35 post‑treatment. The results of the present study suggested that BYHWD may inhibit angiogenesis and metastasis by affecting the expression levels of VEGF, RGS‑5 and HIF‑1α, and suggested that BYHWD may contribute to the tumor microenvironment and vasculature normalization in HCC.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。